| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
3.69(M) |
| Last
Volume: |
900 |
Avg
Vol: |
59,812 |
| 52
Week Range: |
$0.06 - $0.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Delcampo Ralph |
COO and Princ. Exec. Officer |
• – – |
2011-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
18,333 |
171,216 |
|
- |
|
| Delcampo Ralph |
COO and Princ. Exec. Officer |
• – – |
2010-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
9,000 |
171,216 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-12-20 |
5 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
135,125 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-11-23 |
4 |
D |
$10.92 |
$11,608 |
D/D |
(1,063) |
137,125 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
138,188 |
|
- |
|
| Delcampo Ralph |
COO and Princ. Exec. Officer |
• – – |
2010-11-23 |
4 |
D |
$10.92 |
$15,474 |
D/D |
(1,417) |
180,216 |
|
- |
|
| Delcampo Ralph |
COO and Princ. Exec. Officer |
• – – |
2010-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
181,633 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-11-23 |
4 |
D |
$10.92 |
$12,897 |
D/D |
(1,181) |
105,556 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
106,737 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-09-30 |
5 |
A |
$8.91 |
$6,993 |
D/D |
785 |
106,341 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
102,737 |
|
- |
|
| Horak Ivan D |
EVP, President of R&D and CSO |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
135,188 |
|
- |
|
| Delcampo Ralph |
COO and Principal Exec Officer |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
177,633 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-17 |
4 |
S |
$10.63 |
$2,126,660 |
D/D |
(200,000) |
120,188 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-17 |
4 |
OE |
$7.14 |
$1,748,472 |
D/D |
242,000 |
320,188 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-16 |
4 |
S |
$10.67 |
$18,132 |
D/D |
(1,700) |
78,188 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-16 |
4 |
OE |
$7.14 |
$14,280 |
D/D |
2,000 |
79,888 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-15 |
4 |
S |
$10.81 |
$618,200 |
D/D |
(57,200) |
77,888 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-15 |
4 |
OE |
$6.97 |
$495,278 |
D/D |
70,200 |
135,088 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-02 |
4 |
D |
$10.58 |
$74,949 |
D/D |
(7,084) |
64,888 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
71,972 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2010-08-26 |
4 |
S |
$10.49 |
$104,929 |
D/D |
(10,000) |
106,519 |
|
- |
|
| Ogden Mark L |
VP of Finance & PFOOfficer |
• – – |
2010-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2010-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
116,519 |
|
- |
|
| Salisbury Robert C |
Director |
– • – |
2010-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
49,656 |
|
- |
|
394 Records found
|
|
Page 7 of 16 |
|
|
